(19)
(11) EP 4 815 993 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24837198.1

(22) Date of filing: 20.12.2024
(51) International Patent Classification (IPC): 
A61K 47/54(2017.01)
A61P 25/28(2006.01)
 A61K 47/68(2017.01)
C07K 16/18(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6843; A61K 47/6889; A61K 47/6803; A61K 47/545; C07K 16/18; A61P 25/28; C07K 2317/92; C07K 2317/70; C07K 2317/90; A61K 2039/505
(86) International application number:
PCT/IB2024/063062
(87) International publication number:
WO 2025/134068 (26.06.2025 Gazette 2025/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 22.12.2023 US 202363614396 P
25.07.2024 US 202463675382 P
25.07.2024 US 202463675384 P

(71) Applicant: AC Immune SA
1015 Lausanne (CH)

(72) Inventors:
  • NAMPALLY, Sreenivasachary
    1015 Lausanne (CH)
  • MARTIN, Camille
    1015 Lausanne (CH)
  • KOSCO-VILBOIS, Marie
    1015 Lausanne (CH)
  • ADOLFSSON, Oskar
    1015 Lausanne (CH)
  • PFEIFER, Andrea
    1015 Lausanne (CH)

(74) Representative: Meissner Bolte Partnerschaft mbB 
Patentanwälte Rechtsanwälte Postfach 86 06 24
81633 München
81633 München (DE)

   


(54) ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF